BioSpace News Archive

Helix BioPharma Corp., a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced its financial results for the fiscal third quarter ended April 30, 2021.

Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy in patients with muscle invasive bladder cancer (MIBC).

Landos Biopharma, Inc. announced the successful outcome of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for omilancor, its lead candidate in late-stage clinical development for the treatment of mild-to-moderate active ulcerative colitis patients.

iTeos Therapeutics and GlaxoSmithKline plc announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer.

Moderna, Inc. today announced that it has submitted an authorization application to Swissmedic for use of its COVID-19 vaccine in adolescents.

Nothing Small About It (www.nothingsmallaboutit.com) is a support and educational resource center that spotlights and honors the experiences of people living with small cell lung cancer.

Apollo Endosurgery, Inc. announced that investigators of the Multi-Center ESG Randomized Interventional (MERIT) study have reported based on a preliminary analysis the successful achievement of the study’s primary endpoints.

Paratek Pharmaceuticals, Inc. announced the appointment of Minnie Baylor-Henry, J.D., a recognized leader in the area of food and drug laws and regulations, to the company’s Board of Directors.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community on Wednesday, June 16th.

Certara, a global leader in biosimulation, today announced the addition of Carol Gallagher, Pharm.D., to its board of directors.